Volrustomig
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced Cervical Cancer
Conditions
Locally Advanced Cervical Cancer
Trial Timeline
Sep 22, 2023 → Sep 30, 2030
NCT ID
NCT06079671About Volrustomig
Volrustomig is a phase 3 stage product being developed by AstraZeneca for Locally Advanced Cervical Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06079671. Target conditions include Locally Advanced Cervical Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06943833 | Phase 2 | Active |
| NCT06129864 | Phase 3 | Recruiting |
| NCT06079671 | Phase 3 | Recruiting |
Competing Products
20 competing products in Locally Advanced Cervical Cancer